Newsletter Subscribe

Enter your email address below and subscribe to our newsletter

Patient Education

Share your love

Atsena Completes XLRS Gene Therapy Trial Dosing

Atsena Therapeutics has successfully completed dosing in Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating the subretinal delivery of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study represents an important step forward in developing…

Phenocell & Amarna Win Eurostars Grant

Phenocell SAS and Amarna Therapeutics have been awarded the prestigious Eurostars grant to advance their collaborative gene therapy platform targeting dry age-related macular degeneration (AMD). This partnership combines Phenocell’s innovative in vitro AMD disease model with Amarna’s proprietary gene delivery…

ACELYRIN Halts Izokibep Development | OBN

ACELYRIN has announced that the Phase 2b/3 clinical trial evaluating izokibep for non-infectious, non-anterior uveitis did not achieve its primary endpoint. The trial results did not demonstrate a statistically significant improvement in time to treatment failure versus placebo. Consequently, the…

Top 12 Ophthalmic Drugs That Received FDA Approval

2024 Recap is here! Click to review:Top 8 FDA Approvals in Opthalmology In a series of groundbreaking developments, the FDA has approved a range of innovative drugs in 2023, heralding a new era in ophthalmic treatments. Here’s an in-depth look…

Tenpoint and Visus Merge to Advance Eye Care

Tenpoint Therapeutics Ltd. and Visus Therapeutics Inc. have officially merged, combining their respective ophthalmic therapeutic assets to form a unified entity focused on addressing ocular conditions associated with aging, including presbyopia, cataracts, and geographic atrophy. Key Therapeutics in the Combined…

VSY Biotechnology Appoints Dr. Christian Bach MD

VSY Biotechnology GmbH, a global leader in ophthalmic innovation and research, has announced the appointment of Dr. Christian Bach as the new Managing Director, effective November 1, 2024. Extensive Experience in Medical Devices Dr. Bach brings over 25 years of…

VisiRose Unveils Non-Invasive Therapy for Keratitis

VisiRose, a newly established company formed in collaboration with Provectus Biopharmaceuticals and the Bascom Palmer Eye Institute (BPEI) at the University of Miami Miller School of Medicine, is advancing the development of Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT). This…

Fluoxetine Improves Visual Acuity in Adult Amblyopia

A groundbreaking study conducted by researchers from the Eye Research Center, Farabi Eye Hospital, and Tehran University of Medical Sciences has revealed that fluoxetine, a commonly used antidepressant, significantly improves visual acuity (VA) in adults with amblyopia. The study, led…

Nona Biosciences, Kodiak Partner on Ophthalmic Antibodies

Nona Biosciences has announced a strategic partnership with Kodiak Sciences Inc. to advance the development of innovative multi-target antibodies for treating ophthalmic diseases. This collaboration leverages Nona’s proprietary Harbour Mice platform, a cutting-edge technology designed to generate fully human antibodies,…

Stay informed and not overwhelmed, subscribe now!